ASTERDM767.95

Aster DM Healthcare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHKIMSCOHANCEWOCKPHARMASYNGENEGLANDLALPATHLABMcap ₹39,790 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation987.8254.7264.3
+ Impairment Loss / (Reversal)148.80.20.0
+ Finance Costs410.8127.0123.0
+ Interest Income-4.8-127.0-103.3
+ Fair Value (Gains) / Losses0.00.8-1.9
+ Share-based Payments7.40.00.0
+ Other Non-cash Items49.718.520.6
+ Other — Cash Effects are Investing / Financing0.0-7.01.9
+ Other Reconciling Items0.0-76.90.0
Changes in Working Capital
+ Inventories-303.018.21.2
+ Trade Receivables — Current-221.9-34.5-61.7
+ Other Financial Assets — Non-current0.0-33.2-96.0
+ Other Current Assets-1,699.10.00.0
+ Other Financial Liabilities — Current0.0-91.061.5
+ Other Current Liabilities552.70.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)272.5490.0606.7551.0
+ Total Adjustments (incl. Working Capital)-43.549.6209.5
Cash from Operations (pre-tax)229.1539.6816.1
+ Income Taxes Paid71.3114.5160.2
Cash from Operating Activities157.8425.1655.9
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)796.9346.0469.1
+ Acq of Intangible Assets8.710.78.4
+ Disp of Fixed Assets46.91.90.7
+ Purchase of Investments (Equity / Debt)0.07.93.1
+ Disp of Subsidiaries / Businesses (net)0.07,563.20.0
+ Loans & Advances Made0.073.50.0
+ Loans & Advances Repaid-135.40.00.0
+ Dividends Received — Investing0.30.00.0
+ Interest Received — Investing1.364.467.8
+ Other Inflows / (Outflows) — Investing8.0-1,176.5123.9
Cash from Investing Activities-884.76,014.9-288.2
Cash from Financing Activities
+ Proceeds from Issue of Shares0.00.02.5
+ Proceeds from Exercise of Stock Options0.03.10.0
+ Proceeds — Change in Ownership of Subsidiaries0.013.80.0
+ Payments — Change in Ownership of Subsidiaries0.00.081.9
+ Proceeds from Borrowings1,806.8188.5165.0
+ Repayment of Borrowings0.0216.7150.4
+ Payment of Lease Liabilities481.2114.5131.2
+ Interest Paid210.056.753.2
+ Dividends Paid17.96,175.355.1
+ Other Inflows / (Outflows) — Financing-44.90.00.0
Cash from Financing Activities1,052.8-6,357.8-304.3
Net Changes in Cash (pre-FX)326.082.163.4
+ Effect of FX Rate Changes on Cash6.40.30.1
Net Changes in Cash332.482.463.5
Closing Cash697.5164.6
Reference Items
EBITDA578.0764.5901.0958.0
EBITDA Margin %15.6218.4719.4119.65
Free Cash Flow (CFO − Capex)-647.868.3178.4178.4
Free Cash Flow to Equity-15.5184.2
Free Cash Flow per Basic Share-12.501.323.443.44
Price to Free Cash Flow223.04
Cash Flow to Net Income0.750.081.54
Cash Paid for Taxes71.3114.5160.2
Cash Paid for Interest210.056.753.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.